Factor Model (net -0.8)
Factor Model
net -0.8 2.6 / 10Zasturi ramp accelerates with permanent J code live
Watch: Q1 2026 earnings (May) will show Zasturi's first full quarter post-J-code activation. Meaningful acceleration from the $15.8M Q4 baseline validates the reimbursement unlock thesis and sets up a multi-quarter narrative; flat or declining revenue would signal market adoption remains challenged despite regulatory clarity.
UroGen's Q4 2025 results confirmed the two structural de-risking moves now underway. Zasturi generated $15.8 million in Q4 during its foundational phase, with the permanent J code activated January 1, 2026 — reimbursement clarity is locked in and should drive meaningful acceleration into Q1 2026. The company also refinanced $250 million of debt at 8.25% fixed (down from ~12%), extended maturities to 2030, and secured $75 million in additional non-dilutive capital, removing financing risk through the commercial ramp. Jelmyto remained stable at $94 million in 2025 with 2026 guidance of $97–$101 million (3–7% growth), letting management focus capital and bandwidth on scaling Zasturi.
The refinancing halves UroGen's cost of capital and eliminates the 2027 maturity wall — the company now has runway to 2030 with no structural excuses. Zasturi's commercial story shifts from reimbursement risk to pure execution: the J code is active, cash is extended, and the market either adopts the product or it doesn't. Q1 2026 earnings will be the acid test of whether reimbursement clarity translates to adoption velocity.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when URGN changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.